ArticleCell reports2019

Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells.

Weiwei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.